Tricyclic antidepressants, particularly amitriptyline, are the most widely flagged antidepressants to avoid in older adults. They carry the highest anticholinergic burden of any antidepressant class, which translates to real problems: confusion, constipation, urinary retention, dry mouth, blurred vision, and a measurable increase in dementia risk. But they aren’t the only ones that deserve caution. Several other antidepressants, including some that are otherwise considered safer, pose specific dangers for people over 60.
Why Tricyclic Antidepressants Top the List
Tricyclic antidepressants (TCAs) like amitriptyline, nortriptyline, and imipramine have strong anticholinergic effects, meaning they block a chemical messenger involved in memory, digestion, bladder control, and heart rhythm. On standardized anticholinergic burden scales used in geriatric medicine, drugs are scored from 0 (no effect) to 3 (high effect). Amitriptyline, nortriptyline, and imipramine all score a 3, the maximum, on nearly every scale. That score places them alongside sedating antipsychotics in terms of cognitive risk.
The most common serious cardiovascular complication of tricyclic antidepressants is orthostatic hypotension, a sudden drop in blood pressure when standing. In older adults, this is not just uncomfortable. It causes falls, and falls in people over 65 are a leading cause of hospitalization, hip fractures, and loss of independence. For anyone with preexisting heart conduction problems, TCAs also raise the risk of heart block, a potentially dangerous disruption of the heart’s electrical signaling.
The cognitive effects are equally concerning. Blocking acetylcholine in the brain impairs short-term memory, slows processing speed, and can mimic or worsen early dementia. For older adults already experiencing some age-related cognitive decline, adding a high-anticholinergic drug can push them past a threshold they wouldn’t have crossed otherwise.
Paroxetine: The SSRI That Acts Like a Tricyclic
Among the newer SSRIs, paroxetine stands out as one to avoid in older adults. Unlike sertraline or escitalopram, paroxetine has significant anticholinergic activity, scoring a 3 on multiple anticholinergic burden scales, putting it in the same category as amitriptyline. It causes more sedation than other SSRIs, and it has a short half-life that can produce withdrawal symptoms if a dose is missed, something that happens more often in older adults managing multiple medications.
Paroxetine is specifically named in the American Geriatrics Society Beers Criteria, the most widely used list of potentially inappropriate medications for older adults, as an antidepressant to avoid in this age group.
Citalopram and Heart Rhythm Risks
Citalopram is widely prescribed for depression in older adults, but the FDA issued a safety communication limiting the maximum dose to 20 mg per day for anyone over 60. The reason: citalopram can prolong the QT interval, a measurement of the heart’s electrical cycle. When the QT interval stretches too far, it increases the risk of a dangerous irregular heartbeat called torsades de pointes, which can be fatal.
Older adults are more vulnerable because they metabolize citalopram more slowly, leading to higher blood levels at any given dose. The risk climbs further if you’re also taking other medications that affect heart rhythm or if you have liver impairment. Escitalopram, a closely related drug, carries a similar but somewhat lower risk and doesn’t have the same formal dose cap, though caution still applies.
Low Sodium: A Hidden Risk With All SSRIs
All SSRIs can cause hyponatremia (dangerously low sodium levels) by triggering the body to release too much of a hormone that causes water retention. The body reabsorbs more water than it needs, diluting the sodium in the blood. Symptoms typically appear when sodium drops below 130 mmol/L and include drowsiness, weakness, confusion, and in severe cases, seizures.
About 9% of older adults taking an SSRI alone develop hyponatremia. That number climbs above 10% for those also taking a thiazide diuretic, a common blood pressure medication. Case reports illustrate how dramatic this can be: one 84-year-old’s sodium dropped to 122 mmol/L, and another patient was hospitalized just five days after starting fluoxetine with a sodium level of 110 mmol/L, well into the danger zone. This risk exists across the SSRI class, but it’s highest in the first few weeks of treatment and in people already on diuretics.
Bleeding Risk With Common Drug Combinations
SSRIs reduce platelet function, which means they slightly increase the tendency to bleed. On their own, this effect is usually minor. But older adults frequently take blood thinners, aspirin, or anti-inflammatory painkillers, and the combination can be significant. NSAIDs, anticoagulants, and antidepressants are the three drug groups most frequently involved in gastrointestinal bleeding events in older patients.
Some combinations carry especially high risk. One retrospective study found that combining escitalopram with the blood thinner enoxaparin increased the risk of major bleeding by nearly 19 times. Combining any SSRI with NSAIDs raises the risk of both gastrointestinal and cranial bleeding. Fluoxetine specifically is known to enhance warfarin’s blood-thinning effect, which can push someone from a safe therapeutic range into a dangerous one. If you’re taking a blood thinner or use NSAIDs regularly, this interaction is worth a conversation with your prescriber before starting any SSRI.
The Fall Risk Problem Across Classes
The 2019 American Geriatrics Society Beers Criteria recommend against using SSRIs, SNRIs, and TCAs in older adults with a history of falls or fractures. That’s a broad warning that covers nearly every major antidepressant class. SSRIs cause falls through dizziness, low sodium, and effects on balance. TCAs cause falls through sedation and orthostatic hypotension. SNRIs like venlafaxine can raise blood pressure at higher doses, requiring monitoring, and share some of the same balance-related risks.
Not all SSRIs carry equal fall risk, though. At higher doses, sertraline was associated with a 37% lower risk of recurrent falls compared to citalopram or escitalopram at equivalent doses in a comparative study of older adults. This doesn’t make sertraline risk-free, but it suggests a relative advantage when an SSRI is necessary.
Which Antidepressants Are Generally Safer
SSRIs remain the first-line treatment for depression in older adults because they’re better tolerated overall than tricyclics. Within the SSRI class, sertraline is often favored because it has relatively fewer drug interactions, lower anticholinergic activity (scored at moderate on burden scales, well below amitriptyline or paroxetine), and a comparatively better fall-risk profile at higher doses.
Mirtazapine is sometimes used when insomnia or poor appetite accompanies depression, since it promotes sleep and weight gain. Escitalopram is another common choice, though it shares the QT prolongation concern of citalopram to a lesser degree and showed a higher recurrent fall risk than sertraline at higher cumulative doses.
Regardless of which antidepressant is chosen, baseline testing matters. Clinical guidelines recommend checking sodium levels, kidney and liver function, and getting an ECG before starting treatment in anyone over 65, then monitoring sodium again in the first few weeks. Blood pressure monitoring is particularly important with venlafaxine. These aren’t optional extras; they’re how serious side effects get caught early.
Quick Reference: Antidepressants to Use With Caution
- Amitriptyline, nortriptyline, imipramine (TCAs): Highest anticholinergic burden, orthostatic hypotension, fall risk, cognitive impairment. Generally avoid.
- Paroxetine: High anticholinergic load for an SSRI, sedation, withdrawal symptoms. Generally avoid.
- Citalopram: QT prolongation risk. FDA caps the dose at 20 mg/day for adults over 60.
- Fluoxetine: Long half-life, significant drug interactions (especially with warfarin), hyponatremia risk.
- Any SSRI combined with blood thinners or NSAIDs: Elevated bleeding risk that requires careful evaluation.